Trump Tariffs: Vikas Khemani Lists Top Sectoral Picks — Banking, Pharma In The Spotlight
The banking sector's domain is largely domestic, with next to no exposure abroad, said Khemani, which is an advantage in the current investing environment.
Among the sectors expected to power through the recent tariff-induced uncertainty, pharmaceuticals remain a top pick, says Vikas Khemani. Despite concerns over the current global trade scenario, the founder of Carnelian Asset Management and Advisors believes pharma companies will stay resilient.
"CDMO companies won't be impacted by tariffs either," he added, stating that their their domestic operations will largely remain immune to trade distortions. "Our banks are among the best in the world in terms of asset quality," Khemani said, coming to another sector he is bullish on.
"The banking sector won't be impacted by the global tariff war," he noted, highlighting asset quality capitalisation. The banking sector's domain is largely domestic, with next to no exposure abroad, said Khemani, which is an advantage in the current investing environment.
Khemani also made a case for India's labour cost advantage.
"Tariffs on India are lower than most other Asian countries," he said.
India's performance will be solid as it navigates through the volatility, Khemani concluded. While he acknowledged that no country can come out "completely unscathed," he reiterated that India is structurally better off than her global peers.
